Study title:
Eur Heart J. 1998 Mar;19(3):500-7.
Dipyridamole stress thallium-201 perfusion abnormalities in patients with
hypertrophic cardiomyopathy. Relationship to clinical presentation and outcome.
Yamada M, Elliott PM, Kaski JC, Prasad K, Gane JN, Lowe CM, Doi Eur Heart J. 1998 Mar;19(3):500-7.
Dipyridamole stress thallium-201 perfusion abnormalities in patients with
hypertrophic cardiomyopathy. Relationship to clinical presentation and outcome.
Yamada M, Elliott PM, Kaski JC, Prasad K, Gane JN, Lowe CM, Doi
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Diagnosis [E01]
|
Brands: |
MAH holders: Please see report |
Assessment: |
Active substance: THALLIUM 201T1 CHLORIDE |
ATC code: V09GX01 |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
-
|
-
|